Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2010; 16(46): 5881-5888
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5881
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5881
Table 1 Data about patients enrolled in this study
| Characteristics | Patients, n (%) |
| Sex | |
| Male | 59 (65.6) |
| Female | 31 (34.4) |
| Age (yr) | |
| Median | 53 |
| Range | 23-75 |
| Tumor site | |
| Colon | 39 (43.3) |
| Rectal | 51 (56.7) |
| Combined chemotherapy | |
| Irinotecan-based | 58 (64.4) |
| Oxaliplatin-based | 29 (32.2) |
| Monotherapy | 3 (3.3) |
| Cetuximab use | |
| First line | 29 (32.2) |
| Second line | 23 (25.6) |
| Third line | 28 (31.1) |
| Fourth line or more | 10 (11.1) |
| Response status | |
| Complete response | 3 (3.3) |
| Partial response | 31 (34.4) |
| Stable disease | 35 (38.9) |
| Progressive disease | 21 (23.3) |
-
Citation: Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of
KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010; 16(46): 5881-5888 - URL: https://www.wjgnet.com/1007-9327/full/v16/i46/5881.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i46.5881